Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Morning! Today, we discuss how a cytomegalovirus shot flopped in a late-stage trial for Moderna, and why the company is still training its focus on cancer vaccines. Also, researchers at ESMO outlined clinical guidelines for the use of AI.
Moderna’s CMV vaccine flops…
Moderna’s highly touted cytomegalovirus vaccine — long billed as its next big win after its Covid-19 shot — failed a Phase 3 trial, the company announced yesterday. It showed just 6% to 23% efficacy in blocking infection, and missed its primary endpoint.
Continue to STAT+ to read the full story…
STAT Pharma: The science and business of new drug development
Leave a Reply